PepMix™AAV6(CapsidproteinVP1)
ProductCode:PM-AAV6-VP1
Poolof182overlappingpeptidesfromCapsidproteinVP1ofAdeno-associatedvirus-6forTcellassays(e.g.antigenspecificT-cellstimulationinELISPOT)
Amount:1vialcontaining15nmol(appr.25µg)perpeptide
Purity:>70%(HPLC-MS)
DeliveryFormat:Freezedriedinambertypeglassvial
Application:T-cellassays,Immunemonitoring,AntigenspecificT-cellstimulation,T-cellexpansion,Cellularimmuneresponse,ELISPOT
Indication&Topics:Infection,Genetherapy
DeliveryTime:2-5days
PepMix™PeptidePools
Theuseofcompleteprotein-spanningmixturesofoverlappingpeptides(PepMix)isextremelyefficientforimmunostimulationofT-lymphocytesanddiagnosticapplications.InordertoestablishreliableandvalidatedT-cellassayssuchasELISPOT,appropriatepositiveandnegativecontrolsareessential.SelectionofsuchcontrolshelpstoconfirmproperfunctionalityoftheassayaswellasviABIlityofthecellsused.Inaddition,highqualitycontrolsaremostimportanttoestablishstandardizedassayprotocolsinclinicalsetups.Comparedtocommonlyusedcontrolslikephytohemagglutinin(PHA)andconcanavalinA(ConA)thatstimulateT-cellsaswellasothercelltypesorfulllengthantigens,syntheticpeptidepoolsoffertheadvantageofahighbatch-to-batchreproducibility,applicabilityofreliablechemicalandbiochemicalQC/QAmeasuresandshelfstabilitywhenstoredasfreezedriedaliquots.
BenefitsofPepMix™
-EquivalentorbetterstimulationofCD4+andCD8+T-cellresponsescomparedtowholeproteinantigens
-SimultaneousdetectionofCD4+andCD8+responsesinasinglesample
-ImprovedresponsesinstoredbloodandPBMcellscomparedtowholeproteinantigens
-Morereliableascontrolthanphytohemagglutinin(PHA)andconcanavalinA(ConA)
-High-batch-to-batchreproducibility
-Reliablechemicalandbiochemicalqualitycontrolandqualityassuranceforpeptidesynthesisandpeptidepoolgeneration
-Prolongedshelfstabilitywhenstoredfreezedried
PepMix™AAV6(CapsidproteinVP1)
SelectedReferences
"InVitroStudiesoftheImpactofMaribavironCMV-SpecificCellularImmuneResponses"
Stacheletal.,JClinVirol. (2015)-PMID:26780109
"InductionOfBroad-basedImmunityandProtectiveEfficacybySelf-amplifyingmRNAVaccinesEncodingInfluenzaVirusHemagglutinin"
Brazzolietal.,JournalofVirology (2015)-PMID:26468547
"TargetingofNucleoproteintoChemokineReceptorsbyDNAVaccinationResultsinIncreasedCD8+-mediatedCrossProtectionAgainstInfluenza"
Baranowskaetal.,Vaccine(2015)-PMID:26387432
"CharacteristicsofImmuneMemory10-15yearsAfterPrimaryHepatitisBVaccination"
Hummeletal.,Vaccine(2015)-PMID:n.a.
"TCellsSpecificforDifferentLatentandLyticViralProteinsEfficientlyControlEpstein-BarrVirusTransformedBCells"
Nowakowskaetal.,Cytotherapy(2015)-PMID:26276009
"High-densityPrecultureofPBMCsRestoresDefectiveSensitivityofCirculatingCD8TCellstoVirus-andTumor-derivedAntigens"
Wegneretal.,Blood(2015)-PMID:26024876
"MetabolicRegulationofHepatitisBImmunopathologybyMyeloid-derivedSuppressorCells"
Pallettetal.,NatureMedicine(2015)-PMID:25962123
ApplicationNotes
"DevelopingMulti-HIVAntigenSpecificT-CellsasaComponentofaCureStrategy"
Lametal.(2015)Fulltext
"Peptide-stimulatedExpansionofVirus-specificTcellsForPreventativeTreatmentAfterAllogeneicStemCellTransplantation"
Garyetal.(2015)Fulltext
Testimonials
"Toestablishanovelroleformyeloidderivedsuppressorcells(Pallettetal,Nat.Med.2015)inchronicviralinfection,weutilisedthePepMixCEFPool(extended)aswellasacustomsynthesizedPepMixspanningthecoreregionofHBVgenotypeD.Whereas,theCEFpeptidepoolconsistsof32peptides,eachcorrespondingtoadefinedHLAclassI-restrictedT-cellepitopefromCytomegalo,Epstein-Barr,andInfluenzavirus,thelattercustomPepMixincluded15mericpeptidesoverlappingby10aminoacids.SpecificallythiscompositionenabledustomonitorboththeantiviralCD8+andCD4+TcellresponsesinchronicHBVinfectionandthenon-antigenspecificTcellsthatareknowntomediateimmunopathologyintheliver.OurentireexperiencewithJPT,fromordering/deliverytouseinthelabwasexcellent.Notonlywerethereagentsabletoperformreliablyandconsistentlyinvitrofrombatchtobatch,thecustomerandtechnicalsupportprovidedwascontinuallyavailableandefficientwhenneeded.JPTwillremainour"go-to"companyforpurchasingpeptides."
Dr.LauraJPallett,InfectionandImmunity,UniversityCollegeLondon,UK
PepMix™AAV6(CapsidproteinVP1)
| Application | AntigenspecificT-cellstimulation Immunemonitoring T-cellassays T-cellexpansion |
| ProteinName | Capsidprotein |
| Organism | Adeno-associatedvirus |
| Indication/Topic | Genetherapy |
| Numberofpeptides | 182 |
FurtherInformation:
| Amount | 1vialcontaining15nmol(appr.25µg)perpeptide |
| Specifications | Peptidescan(15merswith11aaoverlap) |
| Documentation | ProtocolandDatasheet |
| Swiss-ProtID | O56137 |
| Sequence | MAADGYLPDWLEDNLSEGIREWWDLKPG APKPKANQQKQDDGRGLVLPGYKYLGPF NGLDKGEPVNAADAAALEHDKAYDQQLK AGDNPYLRYNHADAEFQERLQEDTSFGG NLGRAVFQAKKRVLEPFGLVEEGAKTAP GKKRPVEQSPQEPDSSSGIGKTGQQPAK KRLNFGQTGDSESVPDPQPLGEPPATPA AVGPTTMASGGGAPMADNNEGADGVGNA SGNWHCDSTWLGDRVITTSTRTWALPTY NNHLYKQISSASTGASNDNHYFGYSTPW GYFDFNRFHCHFSPRDWQRLINNNWGFR PKRLNFKLFNIQVKEVTTNDGVTTIANN LTSTVQVFSDSEYQLPYVLGSAHQGCLP PFPADVFMIPQYGYLTLNNGSQAVGRSS FYCLEYFPSQMLRTGNNFTFSYTFEDVP FHSSYAHSQSLDRLMNPLIDQYLYYLNR TQNQSGSAQNKDLLFSRGSPAGMSVQPK NWLPGPCYRQQRVSKTKTDNNNSNFTWT GASKYNLNGRESIINPGTAMASHKDDKD KFFPMSGVMIFGKESAGASNTALDNVMI TDEEEIKATNPVATERFGTVAVNLQSSS TDPATGDVHVMGALPGMVWQDRDVYLQG PIWAKIPHTDGHFHPSPLMGGFGLKHPP PQILIKNTPVPANPPAEFSATKFASFIT QYSTGQVSVEIEWELQKENSKRWNPEVQ YTSNYAKSANVDFTVDNNGLYTEPRPIG TRYLTRPL |
| ProteinLength(aa) | 736 |
JPT肽技术有限公司是创新的基于肽的服务以及产品目录和试剂盒的领先提供商，也是免疫学，蛋白质组学和药物发现项目的研发合作伙伴。JPT的总部和生产基地位于德国柏林。根据DIN EN ISO 9001：2015指南，其所有生产和服务均在德国柏林进行。与合作伙伴公司JPT Peptide Technologies Inc.
JPT总部位于马萨诸塞州波士顿附近的Acton，为制药和生物技术行业的全球客户群以及大学，政府和非营利组织的研究人员提供服务。在过去的十年中，JPT开发了一系列专有技术和一系列独特的产品和服务，以支持蛋白质组学，新型疫苗或免疫疗法的所有开发阶段以及基于肽的药物发现的研究工作。
本网站将在规定时间内给予删除等相关处理。
